Why the study?
Does the presence of cardiovascular complications increase in-hospital mortality in adult patients receiving CAR T-cell therapy?
Population
10,690 hospitalized adult patients (≥18 years) who received CAR T-cell therapy from 2019–2023
Comparison
Presence of cardiovascular complications (CVc) vs Absence of cardiovascular complications
Design
Cohort
Follow-up
in-hospital
Key result
Cardiovascular complications during CAR T-cell therapy were associated with a significantly higher risk of in-hospital mortality compared to no complications (6% vs. 1.7%; OR 3.72; p<0.001).
Authors
Loading...
Cardiovascular complications occur in nearly a quarter of adults hospitalized for CAR T-cell therapy and are associated with a nearly four-fold increased risk of in-hospital mortality.
Cohort (n=10,690)
Yes
Does the presence of cardiovascular complications increase in-hospital mortality in adult patients receiving CAR T-cell therapy?
Effect estimate: OR 3.72
Absolute Event Rate: 6% vs 1.7%
p-value: p=<0.001
Cardiovascular complications occur in nearly a quarter of adults hospitalized for CAR T-cell therapy and are associated with a nearly four-fold increased risk of in-hospital mortality.
Ramakrishnan et al. (2026) conducted a cohort in CAR T-cell therapy (n=10,690). Cardiovascular complications vs. No cardiovascular complications was evaluated on Inpatient mortality (OR 3.72, p=<0.001). Cardiovascular complications during CAR T-cell therapy were associated with a significantly higher risk of in-hospital mortality compared to no complications (6% vs. 1.7%; OR 3.72; p<0.001).